Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer
Date
2023
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Cancer
Abstract
Bladder cancer (BCa) is the sixth most prevalent cancer in men and seventeenth most
prevalent cancer in women worldwide. Current treatment paradigms have limited therapeutic
impact, suggesting an urgent need for the investigation of novel therapies. To best emulate the
progression of human BCa, a pre-clinical intravesical murine model is required in conjunction
with existing non-invasive imaging modalities to detect and evaluate cancer progression. Non-invasive imaging modalities reduce the number of required experimental models while allowing for
longitudinal studies of novel therapies to investigate long-term efficacy. In this review, we discuss
the individual and multi-modal use of non-invasive imaging modalities; bioluminescence imaging
(BLI), micro-ultrasound imaging (MUI), magnetic resonance imaging (MRI), and positron emission
tomography (PET) in BCa evaluation. We also provide an update on the potential and the future
directions of imaging modalities in relation to intravesical murine models of BCa.
Description
Research Article
Keywords
bladder cancer (BCa), murine model, intravesical, bioluminescence imaging (BLI)
Citation
Citation: Relouw, S.; Dugbartey, G.J.; Sener, A. Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer. Cancers 2023, 15, 2381. https://doi.org/ 10.3390/cancers15082381